Skip to main content
Premium Trial:

Request an Annual Quote

Additional PPOs to Cover Signal Genetics Multiple Myeloma Test

NEW YORK (GenomeWeb) – Signal Genetics today announced agreements with three preferred provider organizations to cover the firm's multiple myeloma prognostic molecular diagnostic test.

The deals are with Stratose, USA Managed Care Organization, and Evolutions Health Systems, and provide covered access to Signal Genetics' MyPRS test to more than 21 million patients in the US. In total, more than 93 million patients in the US are covered for the test by payors, the Carlsbad, California-based company said.

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling. Signal Genetics reached an agreement during the summer with America's Choice Provider Network to provide coverage of the assay.